Rubius Therapeutics Inc (RUBY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Rubius Therapeutics Inc (RUBY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2479411D
  • |
  • Pages: 30
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutics (RCT) product candidates. Its products under development are intended for the treatment of phenylketonuria, refractory gout, homocystinuria, hyperoxaluria, R/R aPD1 solid tumor, acute myeloid leukemia (AML) post-allogeneic hematopoietic stem cell transplantation, cancer, pemphigus vulgaris and type 1 diabetes, among others. Rubius Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Rubius Therapeutics Inc (RUBY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Rubius Therapeutics Raises USD100 Million in Venture Financing 10

Rubius Therapeutics Raises Funds through Venture Financing 11

Rubius Therapeutics Raises USD120 Million in Venture Financing 12

Rubius Therapeutics Raises USD25 Million in Venture Financing 13

Licensing Agreements 14

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14

Equity Offering 15

Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15

Rubius Therapeutics Inc-Key Competitors 16

Rubius Therapeutics Inc-Key Employees 17

Rubius Therapeutics Inc-Locations And Subsidiaries 18

Head Office 18

Recent Developments 19

Strategy And Business Planning 19

Sep 19, 2018: Raimondo, State officials break ground on new pharmaceutical manufacturing facility 19

Financial Announcements 20

Aug 31, 2018: Rubius Therapeutics announces second quarter 2018 financial results 20

Corporate Communications 21

Jun 06, 2018: Rubius Therapeutics Names Pablo J. Cagnoni As Chief Executive Officer 21

May 02, 2018: Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors 22

Feb 20, 2018: Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing 23

Feb 01, 2018: Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors 24

Dec 14, 2017: Rubius Therapeutics Strengthens Leadership Team with Appointment of Andrew Oh as Chief Financial Officer 25

Sep 27, 2017: Rubius Therapeutics Appoints Chief Medical Officer; Other Key Leadership Team Hires 26

Aug 08, 2017: Cell therapy pioneer David Epstein expands role with Rubius Therapeutics to become executive chairman 27

Jan 04, 2017: Rubius Therapeutics Announces Appointment of Top Leadership 28

Legal and Regulatory 29

Sep 14, 2018: Rubius Therapeutics added to Russell 2000 and 3000 indexes 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30

List of Figures

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rubius Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Rubius Therapeutics Raises USD100 Million in Venture Financing 10

Rubius Therapeutics Raises Funds through Venture Financing 11

Rubius Therapeutics Raises USD120 Million in Venture Financing 12

Rubius Therapeutics Raises USD25 Million in Venture Financing 13

Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14

Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15

Rubius Therapeutics Inc, Key Competitors 16

Rubius Therapeutics Inc, Key Employees 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Rubius Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com